About Calypso Biotech
Calypso Biotech is a company based in Plan-les-ouates (Switzerland) founded in 2013 by Alain Vicari and Yolande Chvatchko was acquired by Novartis in January 2024. Calypso Biotech has raised $36.39 million across 4 funding rounds from investors including Novartis, Fountain Healthcare Partners and Gilde Healthcare. Calypso Biotech operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and ALX Oncology, among others.
- Headquarter Plan-les-ouates, Switzerland
- Founders Alain Vicari, Yolande Chvatchko
- SectorsHealthcare
- Email••••••••
- Website calypsobiotech.com
- Social LinkedIn
- Acquired by Novartis (Jan 2024)
Funding Insights of Calypso Biotech
Calypso Biotech has successfully raised a total of $36.39M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $9.46 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $36.39M
- Total Rounds 4
- Last Round Series A — $9.46M
- First Round $3.25M
(Mar 2013)
- Investors Count 5
All 4 funding rounds of Calypso Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $9.46M | Series A | – | Fountain Healthcare Partners, Gilde Healthcare | – |
| Feb 2019 | $23.68M | Series A | – | Gilde Healthcare, Inkef | |
| Jul 2016 | – | Grant | – | – | – |
| Mar 2013 | $3.25M | Seed | – | – |
6 investors in total: 6 institutional.
Investors in Calypso Biotech
Calypso Biotech has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Fountain Healthcare Partners and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Risk capital is provided to life sciences entrepreneurs. | – | fh-partners.com | Dublin, Ireland | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Venture capital firm investing in multiple sectors | – | m-ventures.com | Amsterdam, Netherlands | |
AI, deeptech, and healthcare tech companies are funded by Inkef. | – | inkef.com | Amsterdam, Netherlands | |
- | – | jnjinnovation.com | - | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Calypso Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Calypso Biotech
2 people are tracked at Calypso Biotech (2 in leadership).
| Name | Role | Group |
|---|---|---|
Alain Vicari | Co-Founder & CEO | Leadership |
Yolande Chvatchko | Co-Founder | Leadership |
Complete people profiles for Calypso Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Calypso Biotech
4 dated milestones of Calypso Biotech across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Calypso Biotech is founded.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Series A, of $9.5M.
- Exit Acquired by Novartis.
Competitors of Calypso Biotech
Calypso Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and ALX Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Calypso Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calypso Biotech
Complete news archive for Calypso Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Calypso Biotech
10 companies that operate in the same segment as Calypso Biotech (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Calypso Biotech
Calypso Biotech was founded in 2013.
Calypso Biotech is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Alain Vicari is the current CEO of Calypso Biotech. They have also founded this company.
Calypso Biotech is a funded company, having raised a total of $36.39M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3.25M, raised on Mar 2013.
Calypso Biotech was founded in 2013 in the biotechnology sector. Antibody-based therapeutics are developed by the company for gastrointestinal diseases, with a focus on autoimmune and inflammatory conditions. The lead candidate, CALY-002, is a monoclonal antibody designed to inhibit Interleukin-15 for celiac disease and dermatological applications. CALY-001 is targeted at broader autoimmune and inflammatory disorders. Operations center on advancing these therapeutic candidates through research and development.
Calypso Biotech's top competitors include Moderna, BeiGene and Strand Therapeutics.
Calypso Biotech has 6 investors. Key investors include Novartis, Fountain Healthcare Partners, Gilde Healthcare, Johnson & Johnson Innovation, and M-Ventures.
Yes. Calypso Biotech was acquired by Novartis in January 2024.